Wockhardt Investor Presentation May 2015

Wockhardt Limited

Investor Presentation By

Dr. Murtaza Khorakiwala Managing Director

Q4FY15 & FY14-15

Safe Harbor Statement

• Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof.

Investor Presentation May 2015 2

Introduction to Wockhardt Key Business Dynamics

ROW operations Wockhardt Direct operations

USA

UK, Ireland, France, Switz.

India

Mexico

Wockhardt Today


Direct Operations

in India, USA

and Europe

8600 Associates employed in 21

countries

UK Ireland

Wockhardt Today


12

Manufacturing Locations globally

Ankleshwar Daman (2 Plants)

Aurangabad (5 Plants)

Baddi

Chicago

Formulations APIs

9 sites in India

Wockhardt Today


3 R&D Centers

worldwide

USA / UK & India

Key Business Update

Key Business Update


UK MHRA lifted Statement of Non Compliance from L1 Facility and have also restored EU GMP certification of Kadaiya facility.

MGP Facility:- 483 response was found satisfactory from US FDA. US FDA conducted inspection in L1 & Waluj facilities & observed on going improvement

in company's efforts towards compliance.

Obtained QIDP status from US FDA for 2 of its drugs WCK 771 & WCK 2349 for New Drug

Discovery program in Anti-infective research in FY15. Also obtained QIDP status for its third NCE product WCK 4873 during this month. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.

Filed for 267 patents during the Year taking the cumulative filings to 2268 and has been granted 82 patents during the Year taking the cumulative patents granted to 341.

Regulatory Update

Research Update

Q4FY15 Results

Sales – Growth of 4% over Q4FY14


Rs.crore

Growth of 4% in Q4FY15 over Q4FY14

EBITDA – Growth of 11% over Q4FY14


Rs.crore

Growth of 11% in Q4FY15 over Q4FY14

PAT – Decline of 55% over Q4FY14


Rs.crore

De-growth of 55% in Q4FY15 over Q4FY14

FY 14-15 Results

Sales – Decline of 7% over FY 13-14


Rs.crore

Decline of 7% in FY 14-15 over FY 13-14

EBITDA – Declines by 16% over FY 13-14


Rs.crore

Declines by 16% in FY 14-15 over FY 13-14

PAT – Declines by 52% over FY 13-14


Rs.crore

Declines by 52% in FY 14-15 over FY 13-14

Research – 11.5% of Sales in FY14-15


US Business


• Declines by 21% (22% in $ terms)

over Q4FY14.

• Declines by 49% (51% in $ terms)

over FY 13-14.

• During the year 14 ANDA’s filed &

cumulative ANDA’s pending for

approval is 69. 2,150 1,087

-

500

1,000

1,500

2,000

2,500

FY 13-14 FY 14-15

USA

Rs.

cr.

$364

$179

EU Operations UK Operations

• 8 New Approvals received in FY 14-15.

• 11 New Fillings done in FY 14-15 , 1 in Q4FY15.

• UK operation Grows by 36% (grows by 34% £ terms) in

Q4FY15. Grows by 46% (35% in £ terms) in FY 14-15.

• Among top 5 generic company.


Ireland Operations

• Ireland Declines by 11% (6% in € terms) in Q4FY15.

Decline by 10% (11% in € terms) in FY 14-15.

964 1,405 100

300

500

700

900

1,100

1,300

1,500

FY 13-14 FY 14-15

UK

Rs.

cr.

£ 104

£ 141

176 158 -

50

100

150

200

250

FY 13-14 FY 14-15

Ireland

Rs.

cr.

€ 22 € 20

India & Emerging Markets • Total Emerging Markets (Including India)

Grows by 26% for Q4FY15. Grows by 19%

for FY 14-15.

• India Business Grows by 46% for Q4FY15

and Grows by 24% during FY 14-15.

• 2 new products in Q4FY15 and 42 new

products launched in FY 14-15 in India.

• Emerging Market operations declined by

25% in Q4FY15 and grew by 3% during FY

14-15.


998 India

1235 India

302 Em

312 Em

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800

FY 13-14 FY 14-15

India & Emerging Markets (Em)

Rs.

cr.


For investor updates and communication please visit www.wockhardt.com

For Information please contact Arun Khatanhar Tel.: +91 22 71596228 [email protected]

mailto:[email protected]

Documents

Wockhardt Investor Presentation May 2015